Search

Your search keyword '"Basso, U."' showing total 612 results
Start Over Author "Basso, U."
612 results on '"Basso, U."'

152. P.26 Adjuvant treatment for elderly patients with colon cancer in ten Italian medical oncology units

Author

Pasetto, L.M., primary, Falci, C., additional, Basso, U., additional, Gasparini, G., additional, D'Andrea, M., additional, Bonginelli, P., additional, Bajetta, E., additional, Platania, M., additional, Alabisio, O., additional, Miraglia, S., additional, Bertona, E., additional, Oniga, F., additional, Biason, R., additional, Chetrì, M.C., additional, Fedele, P., additional, Massara, G., additional, Romaniello, I., additional, Negru, M.E., additional, Giordano, M., additional, Luchena, G., additional, Buzzi, F., additional, Ricotta, R., additional, Siena, S., additional, and Monfardini, S., additional

Published
2007
Full Text
View/download PDF

169. 838P - Characteristics and Prognostic Factors in 455 Elderly Pts Over 70 with Metastatic Renal Cell Carcinoma (Mrcc) Treated with Target Therapies (Tt) in the Community Setting: an Italian Survey

Author

Fraccon, A.P., Pasini, F., Basso, U., Larussa, F., Valduga, F., Re, G. Lo, Graiff, C., Rosti, G., Bearz, A., Sartori, D., Abeni, C., Grillone, F., Vicario, G., Pegoraro, C., Bassan, F., Da Corte, D., Modonesi, C., Segati, R., Medici, M., and Barile, C.

Published
2014
Full Text
View/download PDF

170. 790P - Activity of Sequential New Drugs (Nds) Post-Docetaxel (Doc) Failure, in Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients (Pts). Update from a Multicenter Italian Experience

Author

Caffo, O., De Giorgi, U., Fratino, L., Facchini, G., Basso, U., Alesini, D., Gasparro, D., Ortega, C., Tucci, M., Verderame, F., Campadelli, E., Re, G. Lo, Sabbatini, R., Donini, M., Procopio, G., Sartori, D., Zucali, P.A., Carrozza, F., D'Angelo, A., and Morelli, F.

Published
2014
Full Text
View/download PDF

175. Ifosfamide-related encephalopathy in elderly patients : report of five cases and review of the literature.

Author

Brunello A, Basso U, Rossi E, Stefani M, Ghiotto C, Marino D, Crivellari G, and Monfardini S

Abstract

Encephalopathy is a serious adverse reaction occurring in 15-30% of patients treated with the alkylating agent ifosfamide. Patients with this adverse effect may experience seizures, drowsiness, confusion and hallucinations of different grades of severity. In this article, we describe five cases of acute CNS toxicity in patients aged >/=65 years of age treated with ifosfamide and we review data on the management and outcome of this serious complication in elderly patients.All five patients experienced symptoms of encephalopathy soon after receiving combination chemotherapy including ifosfamide for different tumours. All of the patients had been assessed by means of a Comprehensive Geriatric Assessment for the presence of associated diseases, disability, cognitive status and depression, and scores were satisfactory in all patients, although case 5 was deemed frail because of cancer-related limitation in movement. In four patients, the antidote methylene blue (methylthioninium chloride) was administered intravenously, with successful recovery in three patients and a fatal outcome in the fourth patient. The fifth patient rapidly recovered after discontinuation of ifosfamide and did not receive methylene blue.The roles of older age, peak ifosfamide concentration, low albumin levels, increased serum creatinine and bulky abdominal disease as predisposing factors for ifosfamide-related encephalopathy in retrospective series are controversial.Although methylene blue has been frequently administered in patients with ifosfamide-related encephalopathy, its efficacy in this context has not been assessed objectively. Thus, careful baseline evaluation of elderly patients and constant clinical observation during infusion, especially during the first course of therapy, are recommended to reduce the risk of severe CNS toxicity from ifosfamide. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

176. High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults.

Author

Brandes, Alba Ariela, Palmisano, Valentina, Pasetto, Lara Maria, Basso, Umberto, Monfardini, Silvio, Brandes, A A, Palmisano, V, Pasetto, L M, Basso, U, and Monfardini, S

Subjects
DRUG therapy, BONE marrow, GLIOMAS, GLIOMA treatment, ANTINEOPLASTIC agents, AUTOGRAFTS, BONE marrow transplantation, BRAIN tumors, CANCER relapse, COMBINED modality therapy, CARMUSTINE
Abstract

High-grade malignant gliomas are inevitably fatal, despite every effort to improve this prognosis, including various radiotherapeutic modalities, radio- and chemotherapeutic associations, and combinations of several drugs. High-dose chemotherapy and autologous bone-marrow transplantation (ABMT) have been increasingly used in the last 10 years for solid tumors, and several phase II studies in high-grade glioma patients have been conducted in the setting of both adjuvant treatment and recurrent disease. The most frequently used drug in the conditioning regimens in BCNU at doses higher than that employed by other regimens in other pathologies (800-1000 mg/m2). These dosages involve a high toxicity that is not balanced by a significant improvement in survival. New drugs and/or regimens must be tested in randomized trials. [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

177. 1655P Association of location of BRCA1/2 pathogenic variants with benefit from PARP-inhibitors in metastatic castration-resistant prostate cancers: Results from the PROGRESS study.

Author

Incorvaia, L., Maruzzo, M., Basso, U., Antonuzzo, L., Rizzo, M., Conteduca, V., Messina, C., Bracarda, S., Mammone, G., Scagliarini, S., Maiorano, B.A., Santoni, M., Facchini, G., Lipari, H., Formisano, L., Malapelle, U., Bazan Russo, T.D., Puglisi, M., Bazan, V., and Russo, A.

Subjects
*CASTRATION-resistant prostate cancer
Published
2024
Full Text
View/download PDF

181. B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules

Author

Trentin, L., Renato Zambello, Sancetta, R., Facco, M., Cerutti, A., Perin, A., Siviero, M., Basso, U., Bortolin, M., Adami, F., Agostini, C., and Semenzato, G.

Subjects
Adult, Male, B-Lymphocytes, Leukemia, Hairy Cell, Antigens, CD, Humans, Female, Middle Aged, Flow Cytometry, Leukemia, Lymphocytic, Chronic, B-Cell, Receptors, Tumor Necrosis Factor, Neoplasm Proteins
Abstract

Several costimulatory molecules play a key role in the differentiation of B lymphocytes and in T-B-cell interactions. In this study, we addressed the question of whether different receptors and counter-receptors may be expressed on malignant B lymphocytes from chronic B-cell malignancies. Using flow cytometry and reverse transcription PCR analyses, the expression of molecules belonging to the tumor necrosis factor receptor (TNFR) and tumor necrosis factor ligand (TNFL) families, as well as the expression of CD80 and CD86 molecules, was analyzed in normal B cells and in different chronic lymphoproliferative disorders of B-cell type, including B-cell chronic lymphocytic leukemia (CLL), mantle cell lymphoma, hairy cell leukemia (HCL), and HCL variant. Different patterns of expression of TNFR and TNFL superfamily molecules were demonstrated among B-cell malignancies. In particular, CD40 was commonly observed on all B cells (both tumor and normal), whereas its ligand (CD40L), which is usually undetectable on resting normal B lymphocytes, was expressed in CLL and HCL but not in other chronic lymphoproliferative disorders. CD27 was not shown in normal B cells, although it was present in all malignancies and with particularly high density in mantle cell lymphoma. CD70 was widely distributed on tumor B lymphocytes, but not on the CD5+ normal counterpart. CD30 was strongly expressed in HCL variant and weakly in B-cell CLL, whereas its ligand showed a wide pattern of expression, including all neoplastic and normal B cells. TNFR II (CD120b) and CD80 were distributed on neoplastic B cells from all groups, usually at an intermediate to high degree of intensity, whereas the CD86 molecule was present at lower intensity than CD80. Finally, reverse transcription PCR analysis confirmed the presence of CD40L, CD30, and CD30L mRNAs in those B cells expressing the corresponding membrane-bound proteins at low density. Our data indicate that TNFR and TNFL molecules are of use clinically both in differentiating B-cell malignancies from the normal counterpart (i.e., CD27, CD70, CD40L, CD30, and CD80) and in defining different chronic B-cell disorders (i.e., CD40L, CD27, and CD30). Interestingly, the observation that several receptors and their ligands (i.e., CD40/CD40L, CD30/CD30L, and CD27/CD70) can be expressed on the same cell suggests that these molecules play a role in initiating and maintaining the neoplastic process by mediating B-T and B-B interactions.

182. Adjuvant treatment for elderly patients with colon cancer. An observational study

Author

Pasetto, L. M., Falci, C., Basso, U., Gasparini, G., D Andrea, M., Bonginelli, P., Bajetta, E., Marco Platania, Alabiso, O., Miraglia, S., Bertona, E., Oniga, F., Biason, R., Chetrì, M. C., Fedele, P., Massara, G., Romaniello, I., Negru, M. E., Luchena, G., Giordano, M., Buzzi, F., Ricotta, R., Siena, S., and Monfardini, S.

Subjects
Aged, 80 and over, Male, Chemotherapy, Adjuvant, Colonic Neoplasms, Age Factors, Humans, Female, Adenocarcinoma, Disease-Free Survival, Aged, Neoplasm Staging, Retrospective Studies
Abstract

Adjuvant 5-fluoruracil-based chemotherapy significantly reduces mortality in patients with stage II-III colon cancer, but is less prescribed with rising age. In this study we were interested in the pattern of adjuvant treatment and possible effects on survival among elderly patients.From January to December 2004, 63 questionnaires on the management of stage II-III resected colon cancer patients aged over 70 years, collected from 10 Italian Centres, were retrospectively examined. Determinants of receipt of adjuvant chemotherapy and their relation to survival were considered.The proportion of elderly patients receiving adjuvant chemotherapy was 79.4%, distinct of age, gender, educational level and comorbidities. Grade 3-4 toxicities were the following: haematological in 4 (8.5.%) patients, mucositis in 4 (8.5%), diarrhoea in 2 (4.2%) and nausea in 1 (2.1%). The disease-free survival (DFS) and overall survival (OS) at two years were 79.9% and 95.6%, respectively. Due to the paucity of events, the impact of prognostic factors (patient's age and comorbidity, tumour stage and grade) on DFS and OS could not be assessed.An increasing proportion of elderly patients with colon cancer may be treated with a tolerability and OS similar to those observed in the younger population. Development of age-based guidelines and increased awareness of both physicians and patients through education is important to prevent undertreatment of those elderly patients who are eligible for chemotherapy.

184. Predictive value of different prognostic factors in breast cancer recurrences: Multivariate analysis using a logistic regression model

Author

Franco Lumachi, Ermani M, Aa, Brandes, Basso S, Basso U, and Boccagni P

Subjects
Adult, menopause, Breast Neoplasms, Breast cancer, CEA, Predictive Value of Tests, HER2, Breast cancer, breast, cancer, early breast cancer, breast diseases, malignancy, tumor marker, CA 15-3, CEA, risk factors, estrogen receptors, HER2, CEA, multivariate analysis, menopause, MIB-1, Ki-67, Humans, cancer, risk factors, early breast cancer, breast, Aged, Aged, 80 and over, breast diseases, estrogen receptors, Middle Aged, Prognosis, MIB-1, Logistic Models, multivariate analysis, tumor marker, Ki-67, Female, Neoplasm Recurrence, Local, CA 15-3, malignancy
Abstract

The aim of this study was to compare the sensitivity of different pre-operative parameters in patients with breast cancer (BC) recurrence using univariate and multivariate analysis.We retrospectively analyzed a series of 387 women (median age 60 years, range 35-83 years) who underwent curative surgery for pT1-2 BC. The patients were divided into two groups: Group 1: 325 (84.0%) patients with no evidence of disease during a median follow-up of 53 months (range 25-149 months) and Group 2: 62 (16.0%) patients who developed local or distant recurrences.Univariate analysis showed significant (p0.01) differences between the two Groups in age, size and grading of the tumor and hormone receptor rate. MIB1 proliferation rate, serum markers CEA and CA 15-3, and lymph node status were not useful in predicting relapse. Multivariate analysis using a logistic regression model showed that only age, size of the tumor and hormone receptor rate independently correlate with the onset of recurrences.There is no clear correlation between BC recurrence and the majority of the prognostic factors available. Multivariate analysis of several pre-operative parameters may help to correctly select the high risk population.

186. Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy.

Author

Houédé, N, Locker, G, Lucas, C, Parra, H Soto, Basso, U, Spaeth, D, Tambaro, R, Basterretxea, L, Morelli, F, Theodore, C, Lusuardi, L, Lainez, N, Guillot, A, Tonini, G, Bielle, J, and Del Muro, X Garcia

Abstract

Background: Platinum-based systemic chemotherapy is considered the backbone for management of advanced urothelial carcinomas. However there is a lack of real world data on the use of such chemotherapy regimens, on patient profiles and on management after treatment failure.Methods: Fifty-one randomly selected physicians from 4 European countries registered 218 consecutive patients in progression or relapse following a first platinum-based chemotherapy. Patient characteristics, tumor history and treatment regimens, as well as the considerations of physicians on the management of urothelial carcinoma were recorded.Results: A systemic platinum-based regimen had been administered as the initial chemotherapy in 216 patients: 15 in the neoadjuvant setting, 61 in adjuvant therapy conditions, 137 in first-line advanced setting and 3 in other conditions. Of these patients, 76 (35 %) were initially considered as cisplatin-unfit, mainly because of renal impairment (52 patients). After platinum failure, renal impairment was observed in 44 % of patients, ECOG Performance Status ≥ 2 in 17 %, hemoglobinemia < 10 g/dL in 16 %, hepatic metastases in 13 %. 80 % of these patients received further anticancer therapy. Immediately after failure of adjuvant/neoadjuvant chemotherapy, most subsequent anticancer treatments were chemotherapy doublets (35/58), whereas after therapy failure in the advanced setting most patients receiving further anticancer drugs were treated with a single agent (80/114). After first progression to chemotherapy, treatment decisions were mainly driven by Performance Status and prior response to chemotherapy (>30 % patients). The most frequent all-settings second anticancer therapy regimen was vinflunine (70 % of single-agent and 42 % of all subsequent treatments), the main reasons evoked by physicians (>1 out of 4) being survival benefit, safety and phase III evidence.Conclusion: In this daily practice experience, a majority of patients with urothelial carcinoma previously treated with a platinum-based therapy received a second chemotherapy regimen, most often a single agent after an initial chemotherapy in the advanced setting and preferably a cytotoxic combination after a neoadjuvant or adjuvant chemotherapy. Performance Status and prior response to chemotherapy were the main drivers of further treatment decisions. [ABSTRACT FROM AUTHOR]

Published
2016

187. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.

Author

Siefker-Radtke, A.O., Matsubara, N., Park, S.H., Huddart, R.A., Burgess, E.F., Özgüroğlu, M., Valderrama, B.P., Laguerre, B., Basso, U., Triantos, S., Akapame, S., Kean, Y., Deprince, K., Mukhopadhyay, S., and Loriot, Y.

Subjects
*CLINICAL trials, *TRANSITIONAL cell carcinoma, *METASTASIS, *PEMBROLIZUMAB, *PROTEIN-tyrosine kinase inhibitors
Abstract

Erdafitinib is an oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor approved to treat locally advanced/metastatic urothelial carcinoma (mUC) in patients with susceptible FGFR3/2 alterations (FGFR alt) who progressed after platinum-containing chemotherapy. FGFR -altered tumours are enriched in luminal 1 subtype and may have limited clinical benefit from anti–programmed death-(ligand) 1 [PD-(L)1] treatment. This cohort in the randomized, open-label phase III THOR study assessed erdafitinib versus pembrolizumab in anti–PD-(L)1-naive patients with mUC. Patients ≥18 years with unresectable advanced/mUC, with select FGFRalt , disease progression on one prior treatment, and who were anti–PD-(L)1-naive were randomized 1 : 1 to receive erdafitinib 8 mg once daily with pharmacodynamically guided uptitration to 9 mg or pembrolizumab 200 mg every 3 weeks. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and safety. The intent-to-treat population (median follow-up 33 months) comprised 175 and 176 patients in the erdafitinib and pembrolizumab arms, respectively. There was no statistically significant difference in OS between erdafitinib and pembrolizumab [median 10.9 versus 11.1 months, respectively; hazard ratio (HR) 1.18; 95% confidence interval (CI) 0.92-1.51; P = 0.18]. Median PFS for erdafitinib and pembrolizumab was 4.4 and 2.7 months, respectively (HR 0.88; 95% CI 0.70-1.10). ORR was 40.0% and 21.6% (relative risk 1.85; 95% CI 1.32-2.59) and median duration of response was 4.3 and 14.4 months for erdafitinib and pembrolizumab, respectively. 64.7% and 50.9% of patients in the erdafitinib and pembrolizumab arms had ≥1 grade 3-4 adverse events (AEs); 5 (2.9%) and 12 (6.9%) patients, respectively, had AEs that led to death. Erdafitinib and pembrolizumab had similar median OS in this anti–PD-(L)1-naive, FGFR -altered mUC population. Outcomes with pembrolizumab were better than assumed and aligned with previous reports in non– FGFR -altered populations. Safety results were consistent with the known profiles for erdafitinib and pembrolizumab in this patient population. • Erdafitinib was not superior to pembrolizumab with similar efficacy outcomes in FGFR -altered, anti -PD-(L)1-naive mUC. • The primary endpoint was not met; median OS was 10.9 months for erdafitinib and 11.1 months for pembrolizumab. • Outcomes with pembrolizumab in mUC with FGFR alterations were similar to those reported for FGFR -unselected populations. • Safety was consistent with known safety profiles for erdafitinib and pembrolizumab; erdafitinib toxicities were manageable. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

188. Video killed the Macintosh star: the definitive risk management experience of E. Profili Hospital in Fabriano on routine pediatric videolaryngoscopy.

Author

Pisello, E., Ciuffreda, M., Silvestri, J., Brugiaferri, L., Sorrenti, S., Basso, U. W., Galante, D., and Piangatelli, C.

Subjects
*TRACHEA intubation, *PREOPERATIVE care
Abstract

Introduction: Airway management in tracheal intubation represents one of the crucial issues in current anaesthesiological practice, in which risk management plays an essential role. At the moment, videolaryngoscopy is considered the main technique to facilitate tracheal intubation and reduce its complications. In the operating block of Profili Hospital in Fabriano videolaryingoscopy has been the routine practice since November 2021. Objectives: Evaluation of the routine use of videolaryngoscopy as a mitigator of clinical risk and unexpected difficulties occurring during tracheal intubation in the pediatric surgical setting. Comparison between Fremantle Videolaryngoscope Scoring System and the Colorado Pediatric Airway Score, a score predicting difficult intubation in children. Material and Methods: Preliminary prospective observational study of 137 pediatric patients (aged from 3 to 16 years of age) undergoing surgery, assessed through the previously mentioned scores and classifications. Results: First attempt tracheal intubation achieved in 95,62% of children, without using any additional device. No intubation was impossible, regardless of the difficulties predicted by the Colorado Pediatric Airway Score and the videolaryngoscopic view obtained. All difficult tracheal intubations not predicted by parameters and scores were successfully performed (2,92% in our case series). Conclusion: Routinary use of videolaryngoscopy has encouraged and optimised teamwork, including training; reduced the time spent in the operating room and the use of additional devices for managing difficult airways; completely decreased clinical risk of difficult intubations, eliminating the impossible ones; made it possible to overcome the limits of the Colorado Pediatric Airway Score, a score predicting difficult intubation in children, allowing us to manage easily any unexpected difficult airways; permitted the hypothesis of abandoning, for the near future, scores and parameters predicting difficult intubation, with huge benefits in terms of time spent on surgical patient preoperative evaluation. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

189. Anesthesiological management of adenotonsillar surgery in pediatric setting: the experience of the Spoke Center E. Profili in Fabriano.

Author

Silvestri, J., Ciuffreda, M., Pisello, E., Basso, U. Winga, Castellana, G., Buonamico, A., Piangatelli, C., Pennacchi, A., and Galante, D.

Subjects
*ADENOTONSILLECTOMY, *OPERATIVE surgery, *PERIOPERATIVE care
Abstract

Adenotonsillectomy is the most frequent otorhinolaryngological surgical procedure performed in pediatric age, where the surgical and anesthesiological field overlap and must be shared; it presents a non-negligible risk of postoperative morbidity and complications and must always be performed in optimal conditions of appropriateness and safety. In E. Profili Hospital in Fabriano, a Level I Spoke center, in order to guarantee an appropriate anesthesiological care for the needs and specificity of the pediatric patients and families, the organization of an adequate perioperative path is of crucial importance, starting from the preoperative anesthesiological evaluation, then continuing on the day of surgery with a proper anesthesiological management until the discharge of the patient after a careful postoperative monitoring. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

190. Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy.

Author

Santoro, A., Comandone, A., Basso, U., Soto Parra, H., De Sanctis, R., Stroppa, E., Marcon, I., Giordano, L., Lutman, F. R., Boglione, A., and Bertuzzi, A.

Subjects
*BENZENESULFONATES, *SOFT tissue tumors, *ANTHRACYCLINES, *LONGITUDINAL method, *PROTEIN-tyrosine kinase inhibitors, *CANCER chemotherapy, *CANCER invasiveness, *TUMOR treatment
Abstract

Introduction We investigated the activity and safety of sorafenib, a multitargeted tyrosine-kinase inhibitor, in patients with advanced soft tissue sarcomas (STS). Patients and methods An open-label nonrandomised multicentre phase II study was conducted in advanced STS patients pre-treated with anthracycline-based chemotherapy. Patients received sorafenib 400 mg twice daily for 28 days. The primary end point was the progression-free survival (PFS) rate at 6 months. Toxicity was assessed. Clinical outcomes were evaluated in all histologies and in leiomyosarcoma (L) and angiovascular sarcomas (A). Results Between November 2006 and January 2010, 101 patients (36 L, 19 A, and 46 others) were enrolled; 76 patients per-protocol (PP) and 100 per intention-to-treat (ITT) were assessable for the primary end point. In the PP analysis, 11 (14.5%) achieved partial response and 25 (32.9%) stable disease; 6-month PFS rates were all histologies, 34.5%; L, 38.4%; and A, 56.3%. In the ITT analysis, 6-month PFS results were 27.1, 35, and 35.5% in all histologies, L, and A, respectively. When stratified by histology, we observed a better PFS favouring leiomyosarcoma versus other histologies (P = 0.033). Treatment was well tolerated. Conclusions Sorafenib appears to be a promising option in leiomyosarcoma patients. This finding warrants further evaluation in histology-driven trials. [ABSTRACT FROM PUBLISHER]

Published
2013
Full Text
View/download PDF

191. Preliminary study: routine use of videolaryngoscopy as a clinical risk mitigator in tracheal intubation of pediatric patients. The risk management experience of E. Profili Hospital in Fabriano.

Author

Pisello, E., Ciuffreda, M., Silvestri, J., Basso, U. W., Galante, D., and Piangatelli, C.

Subjects
*VIDEOLARYNGOSTROBOSCOPY, *CHILD patients
Abstract

Introduction Airway management in tracheal intubation represents one of the crucial issues in current anaesthesiological practice, in which risk management plays an essential role. At the moment, videolaryngoscopy is considered the main technique to facilitate tracheal intubation and reduce its complications. In the operating block of Profili Hospital in Fabriano videolaryingoscopy has been the routine practice since November 2021. Objectives Evaluation of the routine use of videolaryngoscopy as a mitigator of clinical risk and unexpected difficulties occurring during tracheal intubation in the pediatric surgical setting. Comparison between Fremantle Videolaryngoscope Scoring System and the Colorado Pediatric Airway Score, a score predicting difficult intubation in children. Material and Methods Preliminary prospective observational study of 64 pediatric patients (aged from 3 to 16 years of age) undergoing surgery, assessed through the previously mentioned scores and classifications. Results First attempt tracheal intubation achieved in 93,75% of children, without using any additional device. No intubation was impossible, regardless of the difficulties predicted by the Colorado Pediatric Airway Score and the videolaryngoscopic view obtained. All difficult tracheal intubations not predicted by parameters and scores were successfully performed (3,44% in our case series). Conclusion Routinary use of videolaryngoscopy has encouraged and optimised teamwork, including training; reduced the time spent in the operating room and the use of additional devices for managing difficult airways; completely decreased clinical risk of difficult intubations, eliminating the impossible ones; made it possible to overcome the limits of the Colorado Pediatric Airway Score, a score predicting difficult intubation in children, allowing us to manage easily any unexpected difficult airways; permitted the hypothesis of abandoning, for the near future, scores and parameters predicting difficult intubation, with huge benefits in terms of time spent on surgical patient preoperative evaluation. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

192. A challenging case of Francisella Tularensis: teenager's massive lymphoadenopathy caused by an uncommon infectious disease.

Author

Castellana, G., Ciuffreda, M., Pisello, E., Basso, U. W., Silvestri, J., Caimmi, M., Pennacchi, A., Galante, D., and Piangatelli, C.

Subjects
*TULAREMIA, *FRANCISELLA tularensis
Abstract

Tularemia is a potentially fatal, multisystemic infectious disease of humans and some animals caused by Francisella Tularensis bacteria. Up to six forms of clinical manifestations of tularemia have been identified, ulceroglandular tularemia being the most common form. Upper airway manifestations of tularemia include tonsillar hypertrophy and pharyngitis, accompanied by cervical lymphadenopathies. Anatomical alterations of the cervical district represent an additional risk in airways management. Between 2016 and 2019, only three cases of tularemia have been described in Italy, but some authors consider Tularemia underreported, especially in Europe. We describe a case of a 17-year-old boy who presented to our clinic with massive cervical left lymphadenopathy and enlargement of the ipsilateral palatine tonsil associated with fever. The symptoms persisted after antibiotic and corticosteroid treatment. To exclude a lymphoproliferative disease, a full body CT scan with contrast was performed, showing multiple cervical bilateral Castellana et al. Francisella Tularensis in pediatric patient lymphadenopathies, especially on the left side and hypertrophy of the left palatine tonsil and splenomegaly. The biopsy of the left tonsil, performed under general anesthesia, demonstrated a granulomatous inflammation. A more accurate reconstruction of the patient history revealed domestic presence of rabbits. Therefore, serologic and molecular tests for F. Tularensis were performed, with positive results. Proper antibiotic treatment was administered with gradual and complete symptoms regression. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

193. Impact of Surgical Approach on Patient-Reported Outcomes after Radical Prostatectomy: A Propensity Score-Weighted Analysis from a Multicenter, Prospective, Observational Study (The Pros-IT CNR Study)

Author

Antonelli, A., Palumbo, C., Noale, M., Porreca, A., Maggi, S., Simeone, C., Bassi, P., Bertoni, F., Bracarda, S., Buglione, M., Conti, G. N., Corvò, R., Gacci, M., Mirone, V., Montironi, R., Triggiani, L., Tubaro, A., Artibani, W., Crepaldi, G., Graziotti, P., Russi, E., Magrini, Stefano, Muto, M., Pecoraro, G., Ricardi, S., Zagonel, U., Alitto, Anna, Ambrosi, R., Aristei, E., Barbieri, C., Bardari, M., Bardoscia, F., Barra, L., Bartoncini, S., Basso, S., Becherini, U., Bellavita, C., Bergamaschi, R., Berlingheri, F., Berruti, S., Borghesi, M., Bortolus, R., Borzillo, V., Bosetti, D., Bove, G., Bove, P., Brausi, M., Bruni, A., Bruno, G., Brunocilla, E., Buffoli, A., Buttigliero, C., Cacciamani, G., Caldiroli, M., Cardo, G., Carmignani, G., Carrieri, G., Castelli, E., Castrezzati, E., Catalano, G., Cattarino, S., Catucci, F., Cavallini, F. D., Ceccarini, O., Celia, A., Chiancone, F., Chini, T., Cianci, C., Cisternino, A., Collura, D., Corbella, F., Corinti, M., Corsi, P., Cortese, F., Corti, L., Cosimo, De, Cristiano, N., D'Angelillo, O., Pozzo, Da, D'Agostino, L., D'Elia, D., Dandrea, C., Angelis, De, Cobelli, De, Concilio, De, Lisa, De, Luca, De, Stefani, De, Deantoni, A., C. L., Degli, Esposti, Destito, C., Detti, A., Muzio, Di, Stasio, Di, Stefano, Di, Trapani, Di, Difino, D., Falivene, G., Farullo, S., Fedelini, G., Ferrari, P., Ferraù, I., Ferro, F., Fodor, M., Fontana, A., Francesca, F., Francolini, F., Frata, G., Frezza, P., Gabriele, G., Galeandro, P., Garibaldi, M., Gennari, Pietro, Gentilucci, G., Giacobbe, A., Giussani, A., Giusti, L., Gontero, G., Guarneri, P., Guida, A., Gurioli, C., Huqi, A., Imbimbo, D., Ingrosso, C., Iotti, G., Italia, C., Mattina, La, Lamanna, P., Lastrucci, E., Lazzari, L., Liberale, G., Liguori, F., Lisi, G., Lohr, R., Lombardo, F., Lovisolo, R., J. A. J., Ludovico, Giuseppe, Macchione, M., Maggio, N., Malizia, F., Manasse, M., Mandoliti, G., Mantini, G., Marafioti, G., Marciello, L., Marconi, Alberto, Martilotta, M., Marzano, A., Masciullo, S., Maso, S., Massenzo, G., Mazzeo, A., Mearini, E., Medoro, L., Molè, S., Monesi, R., Montanari, G., Montefiore, E., Montesi, F., Morgia, G., Moro, G., Muscas, G., Musio, G., Muto, D., Muzzonigro, P., Napodano, G., Negro, G., Nidini, C. L. A., Ntreta, M., Orsatti, M., Palazzolo, M., Parisi, I., Parma, A., Pavan, P., Pericolini, N., Pinto, M., Pistone, F., Pizzuti, A., Platania, V., Polli, A., Pomara, C., Ponti, G., Porcaro, E., Porpiglia, A. B., Pugliese, F., Pycha, D., Raguso, A., Rampini, G., Randone, Donato, Roboldi, F., Roscigno, V., Ruggieri, M., Ruoppo, M. P., Sanseverino, G., Santacaterina, R., Santarsieri, A., Santoni, M., Scagliarini, R., Scagliotti, Giorgio, Scanzi, V., Scarcia, M., Schiavina, M., Sciarra, R., Sciorio, A., Scolaro, C., Scuzzarella, T., Selvaggio, S., Serao, O., Serni, A., Signor, S., Silvani, M. A., Silvano, M., Silvestris, G., Simone, F., Spagnoletti, V., Spinelli, Matteo, Squillace, G., Tombolini, L., Toninelli, V., Trinchieri, M., Trodella, A., Trodella, L. E., Trombetta, L., Tronnolone, C., Tucci, L., Urzì, M., Valdagni, D., Valeriani, R., Vanoli, M., Vitali, M., Volpe, E., Zaramella, A., Zeccolini, S., Zini, G., Antonelli, A., Palumbo, C., Noale, M., Porreca, A., Maggi, S., Simeone, C., Bassi, P., Bertoni, F., Bracarda, S., Buglione, M., Conti, G. N., Corvo, R., Gacci, M., Mirone, V., Montironi, R., Triggiani, L., Tubaro, A., Artibani, W., Crepaldi, G., Graziotti, P., Russi, E., Magrini Stefano, M., Muto, G., Pecoraro, S., Ricardi, U., Zagonel, V., Alitto Anna, R., Ambrosi, E., Aristei, C., Barbieri, M., Bardari, F., Bardoscia, L., Barra, S., Bartoncini, S., Basso, U., Becherini, C., Bellavita, R., Bergamaschi, F., Berlingheri, S., Berruti, A., Borghesi, M., Bortolus, R., Borzillo, V., Bosetti, D., Bove, G., Bove, P., Brausi, M., Bruni, A., Bruno, G., Brunocilla, E., Buffoli, A., Buttigliero, C., Cacciamani, G., Caldiroli, M., Cardo, G., Carmignani, G., Carrieri, G., Castelli, E., Castrezzati, E., Catalano, G., Cattarino, S., Catucci, F., Cavallini, F. D., Ceccarini, O., Celia, A., Chiancone, F., Chini, T., Cianci, C., Cisternino, A., Collura, D., Corbella, F., Corinti, M., Corsi, P., Cortese, F., Corti, L., de Cosimo, N., Cristiano, O., D'Angelillo, R., Da Pozzo, L., D'Agostino, D., D'Elia, C., Dandrea, M., De Angelis, M., De Angelis, P., De Cobelli, O., De Concilio, B., De Lisa, A., De Luca, S., De Stefani, A., Deantoni, C. L., Degli Esposti, C., Destito, A., Detti, B., Di Muzio, N., Di Stasio, A., Di Stefano, C., Di Trapani, D., Difino, G., Falivene, S., Farullo, G., Fedelini, P., Ferrari, I., Ferrau, F., Ferro, M., Fodor, A., Fontana, F., Francesca, F., Francolini, G., Frata, P., Frezza, G., Gabriele, P., Galeandro, M., Garibaldi, E., Gennari Pietro, G., Gentilucci, A., Giacobbe, A., Giussani, L., Giusti, G., Gontero, P., Guarneri, A., Guida, C., Gurioli, A., Huqi, D., Imbimbo, C., Ingrosso, G., Iotti, C., Italia, C., La Mattina, P., Lamanna, E., Lastrucci, L., Lazzari, G., Liberale, F., Liguori, G., Lisi, R., Lohr, F., Lombardo, R., Lovisolo, J. A. J., Ludovico Giuseppe, M., Macchione, N., Maggio, F., Malizia, M., Manasse, G., Mandoliti, G., Mantini, G., Marafioti, L., Marciello, L., Marconi Alberto, M., Martilotta, A., Marzano, S., Masciullo, S., Maso, G., Massenzo, A., Mazzeo, E., Mearini, L., Medoro, S., Mole, R., Monesi, G., Montanari, E., Montefiore, F., Montesi, G., Morgia, G., Moro, G., Muscas, G., Musio, D., Muto, P., Muzzonigro, G., Napodano, G., Negro, C. L. A., Nidini, M., Ntreta, M., Orsatti, M., Palazzolo, C., Palumbo, I., Parisi, A., Parma, P., Pavan, N., Pericolini, M., Pinto, F., Pistone, A., Pizzuti, V., Platania, A., Polli, C., Pomara, G., Ponti, E., Porcaro, A. B., Porpiglia, F., Pugliese, D., Pycha, A., Raguso, G., Rampini, A., Randone Donato, F., Roboldi, V., Roscigno, M., Ruggieri, M. P., Ruoppo, G., Sanseverino, R., Santacaterina, A., Santarsieri, M., Santoni, R., Scagliarini, S., Scagliotti Giorgio, V., Scanzi, M., Scarcia, M., Schiavina, R., Sciarra, A., Sciorio, C., Scolaro, T., Scuzzarella, S., Selvaggio, O., Serao, A., Serni, S., Signor, M. A., Silvani, M., Silvano, G., Silvestris, F., Simone, V., Spagnoletti, G., Spinelli Matteo, G., Squillace, L., Tombolini, V., Toninelli, M., Trinchieri, A., Trodella, L. E., Trodella, L., Trombetta, C., Tronnolone, L., Tucci, M., Urzi, D., Valdagni, R., Valeriani, M., Vanoli, M., Vitali, E., Volpe, A., Zaramella, S., Zeccolini, G., Zini, G., Antonelli, A, Palumbo, C, Noale, M, Porreca, A, Maggi, S, Simeone, C, Bassi, P, Bertoni, F, Bracarda, S, Buglione, M, Conti, G, Corvo, R, Gacci, M, Mirone, V, Montironi, R, Triggiani, L, Tubaro, A, Artibani, W, Crepaldi, G, Graziotti, P, Russi, E, Magrini Stefano, M, Muto, G, Pecoraro, S, Ricardi, U, Zagonel, V, Alitto Anna, R, Ambrosi, E, Aristei, C, Barbieri, M, Bardari, F, Bardoscia, L, Barra, S, Bartoncini, S, Basso, U, Becherini, C, Bellavita, R, Bergamaschi, F, Berlingheri, S, Berruti, A, Borghesi, M, Bortolus, R, Borzillo, V, Bosetti, D, Bove, G, Bove, P, Brausi, M, Bruni, A, Bruno, G, Brunocilla, E, Buffoli, A, Buttigliero, C, Cacciamani, G, Caldiroli, M, Cardo, G, Carmignani, G, Carrieri, G, Castelli, E, Castrezzati, E, Catalano, G, Cattarino, S, Catucci, F, Cavallini, F, Ceccarini, O, Celia, A, Chiancone, F, Chini, T, Cianci, C, Cisternino, A, Collura, D, Corbella, F, Corinti, M, Corsi, P, Cortese, F, Corti, L, de Cosimo, N, Cristiano, O, D'Angelillo, R, Da Pozzo, L, D'Agostino, D, D'Elia, C, Dandrea, M, De Angelis, M, De Angelis, P, De Cobelli, O, De Concilio, B, De Lisa, A, De Luca, S, De Stefani, A, Deantoni, C, Degli Esposti, C, Destito, A, Detti, B, Di Muzio, N, Di Stasio, A, Di Stefano, C, Di Trapani, D, Difino, G, Falivene, S, Farullo, G, Fedelini, P, Ferrari, I, Ferrau, F, Ferro, M, Fodor, A, Fontana, F, Francesca, F, Francolini, G, Frata, P, Frezza, G, Gabriele, P, Galeandro, M, Garibaldi, E, Gennari Pietro, G, Gentilucci, A, Giacobbe, A, Giussani, L, Giusti, G, Gontero, P, Guarneri, A, Guida, C, Gurioli, A, Huqi, D, Imbimbo, C, Ingrosso, G, Iotti, C, Italia, C, La Mattina, P, Lamanna, E, Lastrucci, L, Lazzari, G, Liberale, F, Liguori, G, Lisi, R, Lohr, F, Lombardo, R, Lovisolo, J, Ludovico Giuseppe, M, Macchione, N, Maggio, F, Malizia, M, Manasse, G, Mandoliti, G, Mantini, G, Marafioti, L, Marciello, L, Marconi Alberto, M, Martilotta, A, Marzano, S, Masciullo, S, Maso, G, Massenzo, A, Mazzeo, E, Mearini, L, Medoro, S, Mole, R, Monesi, G, Montanari, E, Montefiore, F, Montesi, G, Morgia, G, Moro, G, Muscas, G, Musio, D, Muto, P, Muzzonigro, G, Napodano, G, Negro, C, Nidini, M, Ntreta, M, Orsatti, M, Palazzolo, C, Palumbo, I, Parisi, A, Parma, P, Pavan, N, Pericolini, M, Pinto, F, Pistone, A, Pizzuti, V, Platania, A, Polli, C, Pomara, G, Ponti, E, Porcaro, A, Porpiglia, F, Pugliese, D, Pycha, A, Raguso, G, Rampini, A, Randone Donato, F, Roboldi, V, Roscigno, M, Ruggieri, M, Ruoppo, G, Sanseverino, R, Santacaterina, A, Santarsieri, M, Santoni, R, Scagliarini, S, Scagliotti Giorgio, V, Scanzi, M, Scarcia, M, Schiavina, R, Sciarra, A, Sciorio, C, Scolaro, T, Scuzzarella, S, Selvaggio, O, Serao, A, Serni, S, Signor, M, Silvani, M, Silvano, G, Silvestris, F, Simone, V, Spagnoletti, G, Spinelli Matteo, G, Squillace, L, Tombolini, V, Toninelli, M, Trinchieri, A, Trodella, L, Trombetta, C, Tronnolone, L, Tucci, M, Urzi, D, Valdagni, R, Valeriani, M, Vanoli, M, Vitali, E, Volpe, A, Zaramella, S, Zeccolini, G, and Zini, G

Subjects
Male, Patient-reported outcome measures, Prostate cancer, Quality of life, Radical prostatectomy, Sexual function, Urinary function, Patient Reported Outcome Measure, medicine.medical_treatment, 030232 urology & nephrology, Longitudinal Studie, Aged, Data Collection, Humans, Italy, Longitudinal Studies, Middle Aged, Patient Reported Outcome Measures, Prospective Studies, Prostate, Prostatectomy, Prostatic Neoplasms, Quality of Life, Retrospective Studies, Robotic Surgical Procedures, Surveys and Questionnaires, Treatment Outcome, Propensity Score, 0302 clinical medicine, Retrospective Studie, Medicine, Surveys and Questionnaire, Prospective cohort study, Patient-reported outcome measure, 030220 oncology & carcinogenesis, Human, medicine.medical_specialty, Robotic Surgical Procedure, Urology, 03 medical and health sciences, Clinical significance, business.industry, Retrospective cohort study, Prospective Studie, Propensity score matching, Prostatic Neoplasm, Observational study, business
Abstract

Background: To report health-related quality of life outcomes as assessed by validated patient-reported outcome measures (PROMs) after radical prostatectomy (RP). ­Methods: This study analyzed patients treated with RP within The PROState cancer monitoring in Italy, from the National Research Council (Pros-IT CNR). Italian versions of Short-Form Heath Survey and university of California los Angeles-prostate cancer index questionnaires were administered. PROMs were physical composite scores, mental composite scores and urinary, bowel, sexual functions and bothers (UF/B, BF/B, SF/B). Baseline unbalances were controlled with propensity scores and stabilized inverse weights; differences in PROMs between different RP approaches were estimated by mixed models. Results: Of 541 patients treated with RP, 115 (21%) received open RP (ORP), 90 (17%) laparoscopic RP (LRP) and 336 (61%) robot-assisted RP (RARP). At head-to-head ­comparisons, RARP showed higher 12-month UF vs. LRP (interaction treatment * time p = 0.03) and 6-month SF vs. ORP (p < 0.001). At 12-month from surgery, 67, 73 and 79% of patients used no pad for urinary loss in ORP, LRP and RARP respectively (no differences for each comparison). Conversely, 16, 27 and 40% of patients declared erections firm enough for sexual intercourse in ORP, LRP and RARP respectively (only significant difference for ORP vs. RARP, p = 0.0004). Conclusions: Different RP approaches lead to significant variations in urinary and sexual PROMs, with a general trend in favour of RARP. However, their clinical significance seems limited.

Published
2019

194. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Author

Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., Judrez, V. M. Oyervides, Hsieh, J J, Basso, U., Shah, A. Y., Sudrez, C., Hamzaj, A., Goh, J. C., Barrios, C., Richardet, M., Porta, C., kowalyszyn, R., Feregrino, J. P., Zotnierek, J., and Pook, D.

Subjects
*DRUG side effects, *DRUG efficacy, *QUALITY of life, *PROGRESSION-free survival, *CARCINOMA
Abstract

BACKGROUND The efficacy and safety of nivolumab plus cabozantinib as compared with those of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not known. METHODS In this phase 3, randomized, open-label trial, we randomly assigned adults with previously untreated clear-cell, advanced renal-cell carcinoma to receive either nivolumab (240 mg every 2 weeks) plus cabozantinib (40 mg once daily) or sunitinib (50 mg once daily for 4 weeks of each 6-week cycle). The primary end point was progression-free survival, as determined by blinded independent central review. Secondary end points included overall survival, objective response as determined by independent. review, and safety. Health-related quality of life was an exploratory end point. RESULTS Overall, 651 patients were assigned to receive nivolumab plus cabozantinib (323 N patients) or sunitinib (328 patients). At a median follow-up of 18.1 months for c overall survival, the median progression-free survival was 16.6 months (95% confidence interval [CI], 12.5 to 24.9) with nivolumab plus cabozantinib and 8.3 months (95% CI, 7.0 to 9.7) with sunitinib (hazard ratio for disease progression or death, 0.51; 95% CI, 0.41 to 0.64; P<0.001). The probability of overall survival at 12 months was 85.7% (95% CI, 81.3 to 89.1) with nivolumab plus cabozantinib and 75.6% (95% CI, 70.5 to 80.0) with sunitinib (hazard ratio for death, 0.60; 98.89% CI, 0.40 to 0.89; P=0,001). An objective response occurred in 55.7% of the patients receiving nivolumab plus cabozantinib and in 27.1% of those receiving sunitinib (P<0.001). Efficacy benefits with nivolumab plus cabozantinib were consistent across subgroups. Adverse events of any cause of grade 3 or higher occurred in 75.3% of the 320 patients receiving nivolumab plus cabozantinib and in 70.6% of the 320 patients receiving sunitinib. Overall, 19.7% of the patients in the combination group discontinued at least one of the trial drugs owing to adverse events, and 5.6% discontinued both. Patients reported better health-related quality of life with nivolumab plus cabozantinib than with sunitinib. CONCLUSIONS Nivolumab plus cabozantinib had significant benefits over sunitinib with respect to progression-free survival, overall survival, and likelihood of response in patients with previously untreated advanced renal-cell carcinoma. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

195. Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: The Pros-IT CNR study

Author

Angelo, Porreca, Marianna, Noale, Walter, Artibani, Pier Francesco Bassi, Filippo, Bertoni, Sergio, Bracarda, Giario Natale Conti, Renzo, Corvò, Mauro, Gacci, Pierpaolo, Graziotti, Magrini, STEFANO MARIA, Vincenzo, Mirone, Rodolfo, Montironi, Giovanni, Muto, Stefano, Pecoraro, Umberto, Ricardi, Elvio, Russi, Andrea, Tubaro, Vittorina, Zagonel, Gaetano, Crepaldi, Stefania, Maggi, Pierfrancesco, Bassi, Stefano Maria Magrini, Anna Rita Alitto, Enrica, Ambrosi, Alessandro, Antonelli, Cynthia, Aristei, Michele, Barbieri, Franco, Bardari, Lilia, Bardoscia, Salvina, Barra, Sara, Bartoncini, Umberto, Basso, Carlotta, Becherini, Rita, Bellavita, Franco, Bergamaschi, Stefania, Berlingheri, Berruti, Alfredo, Marco, Borghesi, Roberto, Bortolus, Valentina, Borzillo, Davide, Bosetti, Giuseppe, Bove, Pierluigi, Bove, Maurizio, Brausi, Alessio, Bruni, Giorgio, Bruno, Eugenio, Brunocilla, Alberto, Buffoli, BUGLIONE DI MONALE E BASTIA, Michela, Consuelo, Buttigliero, Giovanni, Cacciamani, Michela, Caldiroli, Giuseppe, Cardo, Giorgio, Carmignani, Giuseppe, Carrieri, Emanuele, Castelli, Elisabetta, Castrezzati, Gianpiero, Catalano, Susanna, Cattarino, Francesco, Catucci, Francolini Dario Cavallini, Ofelia, Ceccarini, Antonio, Celia, Francesco, Chiancone, Tommaso, Chini, Claudia, Cianci, Antonio, Cisternino, Devis, Collura, Franco, Corbella, Matteo, Corinti, Paolo, Corsi, Fiorenza, Cortese, Luigi, Corti, Cosimo de Nunzio, Olga, Cristiano, Rolando, M D'Angelillo, Luigi Da Pozzo, Daniele, D'Agostino, Carolina, D'Elia, Matteo, Dandrea, Michele De Angelis, Paolo De Angelis, Ottavio De Cobelli, Bernardino De Concilio, Antonello De Lisa, Stefano De Luca, Agostina De Stefani, Chiara Lucrezia Deantoni, Esposti Claudio Degli, Anna, Destito, Beatrice, Detti, Nadia Di Muzio, Andrea Di Stasio, Calogero Di Stefano, Danilo Di Trapani, Giuseppe, Difino, Sara, Falivene, Giuseppe, Farullo, Paolo, Fedelini, Ilaria, Ferrari, Francesco, Ferrau, Matteo, Ferro, Andrei, Fodor, Francesco, Fontanta, Francesco, Francesca, Giulio, Francolini, Paolo, Frata, Giovanni, Frezza, Pietro, Gabriele, Maria, Galeandro, Elisabetta, Garibaldi, Pietro Giovanni Gennari, Alessandro, Gentilucci, Alessandro, Giacobbe, Laura, Giussani, Giuseppe, Giusti, Paolo, Gontero, Alessia, Guarneri, Cesare, Guida, Alberto, Gurioli, Dorijan, Huqi, Ciro, Imbimbo, Gianluca, Ingrosso, Cinzia, Iotti, Corrado, Italia, Pierdaniele La Mattina, Enza, Lamanna, Luciana, Lastrucci, Grazia, Lazzari, Fabiola, Liberale, Giovanni, Liguori, Roberto, Lisi, Frank, Lohr, Riccardo, Lombardo, Jon A, J Lovisolo, Giuseppe Mario Ludovico, Nicola, Macchione, Francesca, Maggio, Michele, Malizia, Gianluca, Manasse, Giovanni, Mandoliti, Giovanna, Mantini, Luigi, Marafioti, Luisa, Marciello, Alberto Mario Marconi, Antonietta, Martilotta, Salvino, Marzano, Stefano, Masciullo, Gloria, Maso, Adele, Massenzo, Ercole, Mazzeo, Luigi, Mearini, Serena, Medoro, Rosa, Molè, Giorgio, Monesi, Emanuele, Montanari, Franco, Montefiore, Giampaolo, Montesi, Giuseppe, Morgia, Gregorio, Moro, Giorgio, Muscas, Daniela, Musio, Paolo, Muto, Giovanni, Muzzonigro, Giorgio, Napodano, Carlo Luigi Augusto Negro, Mattia, Nidini, Maria, Ntreta, Marco, Orsatti, Carmela, Palazzolo, Isabella, Palumbo, Alessandro, Parisi, Paolo, Parma, Nicola, Pavan, Martina, Pericolini, Francesco, Pinto, Antonio, Pistone, Valerio, Pizzuti, Angelo, Platania, Caterina, Polli, Giorgio, Pomara, Elisabetta, Ponti, Antonio Benito Porcaro, Francesco, Porpiglia, Dario, Pugliese, Armin, Pycha, Giuseppe, Raguso, Andrea, Rampini, Donato Franco Randone, Valentina, Roboldi, Marco, Roscigno, Maria Paola Ruggieri, Giuseppe, Ruoppo, Roberto, Sanseverino, Anna, Santacaterina, Michele, Santarsieri, Riccardo, Santoni, Sarah, Scagliarini, Giorgio Vittorio Scagliotti, Mauro, Scanzi, Marcello, Scarcia, Riccardo, Schiavina, Alessandro, Sciarra, Carmine, Sciorio, Tindaro, Scolaro, Salvatore, Scuzzarella, Oscar, Selvaggio, Armando, Serao, Sergio, Serni, Marco Andrea Signor, Mauro, Silvani, Giovanni, Silvano, Franco, Silvestris, Simeone, Claudio, Valeria, Simone, Girolamo, Spagnoletti, Matteo Giulio Spinelli, Luigi, Squillace, Vincenzo, Tombolini, Mariastella, Toninelli, Triggiani, Luca, Alberto, Trinchieri, Luca Eolo Trodella, Lucio, Trodella, Carlo, Trombetta, Lidia, Tronnolone, Marcello, Tucci, Daniele, Urzì, Riccardo, Valdagni, Maurizio, Valeriani, Maurizio, Vanoli, Elisabetta, Vitali, Alessandro, Volpe, Stefano, Zaramella, Guglielmo, Zeccolini, Giampaolo, Zini, Porreca, Angelo, Noale, Marianna, Artibani, Walter, Bassi, Pier Francesco, Bertoni, Filippo, Bracarda, Sergio, Conti, Giario Natale, Corvò, Renzo, Gacci, Mauro, Graziotti, Pierpaolo, Magrini, Stefano Maria, Mirone, Vincenzo, Montironi, Rodolfo, Muto, Giovanni, Pecoraro, Stefano, Ricardi, Umberto, Russi, Elvio, Tubaro, Andrea, Zagonel, Vittorina, Crepaldi, Gaetano, Maggi, Stefania, Gaetano, Crepaldi, Umberto, Basso, Luigi, Corti, D'Agostino, Daniele, Matteo, Dandrea, Davide, Bosetti, Gianpiero, Catalano, Ottavio, De Cobelli, Lucrezia, Deantoni Chiara, Nadia, Di Muzio, Ferro, Matteo, Andrei, Fodor, Pierdaniele, La Mattina, Emanuele, Montanari, Barbieri, Michele, Valentina, Borzillo, Chiancone, Francesco, Sara, Falivene, Paolo, Fedelini, Imbimbo, Ciro, Paolo, Muto, Sarah, Scagliarini, Giovanni, Muzzonigro, Enrica, Ambrosi, Alessandro, Antonelli, Lilia, Bardoscia, Stefania, Berlingheri, Alfredo, Berruti, Alberto, Buffoli, Michela, Buglione, Mauro, Scanzi, Elisabetta, Castrezzati, Paolo, Frata, Giulio, Francolini, Beatrice, Detti, Tommaso, Chini, Carlotta, Becherini, Olga, Cristiano, Cesare, Guida, Sara, Bartoncini, Consuelo, Buttigliero, Emanuele, Castelli, Devis, Collura, Stefano, De Luca, Pietro, Gabriele, Elisabetta, Garibaldi, Alessandro, Giacobbe, Paolo, Gontero, Alessia, Guarneri, Alberto, Gurioli, Francesco, Porpiglia, Franco, Randone Donato, Vittorio, Scagliotti Giorgio, Cynthia, Aristei, Rita, Bellavita, Isabella, Palumbo, Franco, Bardari, Augusto, Negro Carlo Luigi, Franco, Bergamaschi, Maria, Galeandro, Cinzia, Iotti, Giuseppe, Raguso, Paola, Ruggieri Maria, Giuseppe, Ruoppo, Marco, Borghesi, Eugenio, Brunocilla, Claudio, Degli Esposti, Giovanni, Frezza, Michele, Malizia, Maria, Ntreta, Alessandro, Parisi, Riccardo, Schiavina, Roberto, Bortolu, Giuseppe, Bove, Antonio, Cisternino, Carrieri, Giuseppe, Giuseppe, Difino, Oscar, Selvaggio, Maurizio, Brausi, Alessio, Bruni, Frank, Lohr, Ercole, Mazzeo, Enza, Lamanna, Calogero, Di Stefano, Giorgio, Bruno, Michela, Caldiroli, Ilaria, Ferrari, Laura, Giussani, Lovisolo Jon, A. J., Mario, Marconi Alberto, Giuseppe, Cardo, Mario, Ludovico Giuseppe, Marcello, Scarcia, Giorgio, Carmignani, Salvina, Barra, Dario, Cavallini Francolini, Franco, Corbella, Ofelia, Ceccarini, Luigi, Da Pozzo, Agostina, De Stefani, Corrado, Italia, Stefano, Masciullo, Valentina, Roboldi, Marco, Roscigno, Antonio, Celia, Bernardino, De Concilio, Claudia, Cianci, Francesco, Francesca, Giorgio, Pomara, Michele, Santarsieri, Fiorenza, Cortese, Andrea, Di Stasio, Franco, Montefiore, Armando, Serao, D'Elia, Carolina, Armin, Pycha, Dorijan, Huqi, Paolo, De Angeli, Nicola, Macchione, Francesco, Fontanta, Giorgio, Monesi, Antonello, De Lisa, Giuseppe, Giusti, Giorgio, Musca, Anna, Destito, Rosa, Molè, Danilo, Di Trapani, Francesco, Ferrau, Carmela, Palazzolo, Angelo, Platania, Anna, Santacaterina, Grazia, Lazzari, Fabiola, Liberale, Gregorio, Moro, Giovanni, Liguori, Nicola, Pavan, Francesca, Maggio, Marco, Orsatti, Giovanni, Mandoliti, Giampaolo, Montesi, Luigi, Marafioti, Antonietta, Martilotta, Adele, Massenzo, Luisa, Marciello, Salvino, Marzano, Caterina, Polli, Gloria, Maso, Serena, Medoro, Giuseppe, Morgia, Napodano, Giorgio, Pistone, Antonio, Roberto, Sanseverino, Mattia, Nidini, Paolo, Parma, Valerio, Pizzuti, Sciorio, Carmine, Scuzzarella, Salvatore, Tindaro, Scolaro, Porreca A, Noale M, Artibani W, Bassi PF, Bertoni F, Bracarda S, Conti GN, Corvò R, Gacci M, Graziotti P, Magrini SM, Mirone V, Montironi R, Muto G, Pecoraro S, Ricardi U, Russi E, Tubaro A, Zagonel V, Crepaldi G, Maggi S, Crepaldi G, Maggi S, Noale M, Porreca A, Artibani W, Bassi P, Bracarda S, Conti GN, Corvò R, Graziotti P, Russi E, Mirone V, Montironi R, Bertoni F, Gacci M, Magrini SM, Muto G, Pecoraro S, Ricardi U, Tubaro A, Zagonel V, Alitto AR, Ambrosi E, Antonelli A, Aristei C, Barbieri M, Bardari F, Bardoscia L, Barra S, Bartoncini S, Basso U, Becherini C, Bellavita R, Bergamaschi F, Berlingheri S, Berruti A, Borghesi M, Bortolus R, Borzillo V, Bosetti D, Bove G, Bove P, Brausi M, Bruni A, Bruno G, Brunocilla E, Buffoli A, Buglione M, Buttigliero C, Cacciamani G, Caldiroli M, Cardo G, Carmignani G, Carrieri G, Castelli E, Castrezzati E, Catalano G, Cattarino S, Catucci F, Cavallini FD, Ceccarini O, Celia A, Chiancone F, Chini T, Cianci C, Cisternino A, Collura D, Corbella F, Corinti M, Corsi P, Cortese F, Corti L, de Nunzio C, Cristiano O, D'Angelillo RM, Da Pozzo L, D'agostino D, D'Elia C, Dandrea M, De Angelis M, De Angelis P, De Cobelli O, De Concilio B, De Lisa A, De Luca S, De Stefani A, Deantoni CL, Degli EC, Destito A, Detti B, Di Muzio N, Di Stasio A, Di Stefano C, Di Trapani D, Difino G, Falivene S, Farullo G, Fedelini P, Ferrari I, Ferrau F, Ferro M, Fodor A, Fontanta F, Francesca F, Francolini G, Frata P, Frezza G, Gabriele P, Galeandro M, Garibaldi E, Gennari PG, Gentilucci A, Giacobbe A, Giussani L, Giusti G, Gontero P, Guarneri A, Guida C, Gurioli A, Huqi D, Imbimbo C, Ingrosso G, Iotti C, Italia C, La Mattina P, Lamanna E, Lastrucci L, Lazzari G, Liberale F, Liguori G, Lisi R, Lohr F, Lombardo R, Lovisolo JAJ, Ludovico GM, Macchione N, Maggio F, Malizia M, Manasse G, Mandoliti G, Mantini G, Marafioti L, Marciello L, Marconi AM, Martilotta A, Marzano S, Masciullo S, Maso G, Massenzo A, Mazzeo E, Mearini L, Medoro S, Molè R, Monesi G, Montanari E, Montefiore F, Montesi G, Morgia G, Moro G, Muscas G, Musio D, Muto P, Muzzonigro G, Napodano G, Negro CLA, Nidini M, Ntreta M, Orsatti M, Palazzolo C, Palumbo I, Parisi A, Parma P, Pavan N, Pericolini M, Pinto F, Pistone A, Pizzuti V, Platania A, Polli C, Pomara G, Ponti E, Porcaro AB, Porpiglia F, Pugliese D, Pycha A, Raguso G, Rampini A, Randone DF, Roboldi V, Roscigno M, Ruggieri MP, Ruoppo G, Sanseverino R, Santacaterina A, Santarsieri M, Santoni R, Scagliarini S, Scagliotti GV, Scanzi M, Scarcia M, Schiavina R, Sciarra A, Sciorio C, Scolaro T, Scuzzarella S, Selvaggio O, Serao A, Serni S, Signor MA, Silvani M, Silvano G, Silvestris F, Simeone C, Simone V, Spagnoletti G, Spinelli MG, Squillace L, Tombolini V, Toninelli M, Triggiani L, Trinchieri A, Trodella LE, Trodella L, Trombetta C, Tronnolone L, Tucci M, Urzì D, Valdagni R, Valeriani M, Vanoli M, Vitali E, Volpe A, Zaramella S, Zeccolini G, Zini G, Porreca, A., Noale, M., Artibani, W., Bassi, P. F., Bertoni, F., Bracarda, S., Conti, G. N., Corvo, R., Gacci, M., Graziotti, P., Magrini, S. M., Mirone, V., Montironi, R., Muto, G., Pecoraro, S., Ricardi, U., Russi, E., Tubaro, A., Zagonel, V., Crepaldi, G., Maggi, S., Alitto, A. R., Ambrosi, E., Antonelli, A., Aristei, C., Barbieri, M., Bardari, F., Bardoscia, L., Barra, S., Bartoncini, S., Basso, U., Becherini, C., Bellavita, R., Bergamaschi, F., Berlingheri, S., Berruti, A., Borghesi, M., Bortolus, R., Borzillo, V., Bosetti, D., Bove, G., Bove, P., Maurizio, B., Alessio, B., Giorgio, B., Eugenio, B., Alberto, B., Michela, B., Consuelo, B., Giovanni, C., Michela, C., Giuseppe, C., Giorgio, C., Emanuele, C., Elisabetta, C., Gianpiero, C., Susanna, C., Catucci, F., Dario, C. F., Ofelia, C., Antonio, C., Francesco, C., Tommaso, C., Claudia, C., Devis, C., Franco, C., Matteo, C., Paolo, C., Fiorenza, C., Luigi, C., Cosimo, N., Cristiano, O., D'Angelillo, R. M., Da Pozzo, L., D'Agostino, D., D'Elia, C., Dandrea, M., De Angelis, M., De Angelis, P., De Cobelli, O., De Concilio, B., De Lisa, A., De Luca, S., De Stefani, A., Deantoni, C. L., Degli, E. C., Destito, A., Detti, B., Di Muzio, N., Di Stasio, A., Di Stefano, C., Di Trapani, D., Difino, G., Falivene, S., Farullo, G., Fedelini, P., Ferrari, I., Ferrau, F., Ferro, M., Fodor, A., Fontanta, F., Francesca, F., Francolini, G., Frata, P., Frezza, G., Gabriele, P., Galeandro, M., Garibaldi, E., Gennari, P. G., Gentilucci, A., Giacobbe, A., Giussani, L., Giusti, G., Gontero, P., Guarneri, A., Guida, C., Gurioli, A., Huqi, D., Imbimbo, C., Ingrosso, G., Iotti, C., Italia, C., La Mattina, P., Lamanna, E., Lastrucci, L., Lazzari, G., Liberale, F., Liguori, G., Lisi, R., Lohr, F., Lombardo, R., Lovisolo, J. A. J., Ludovico, G. M., Macchione, N., Maggio, F., Malizia, M., Manasse, G., Mandoliti, G., Mantini, G., Marafioti, L., Marciello, L., Marconi, A. M., Martilotta, A., Marzano, S., Masciullo, S., Maso, G., Massenzo, A., Mazzeo, E., Mearini, L., Medoro, S., Mole, R., Monesi, G., Montanari, E., Montefiore, F., Montesi, G., Morgia, G., Moro, G., Muscas, G., Musio, D., Muto, P., Muzzonigro, G., Napodano, G., Negro, C. L. A., Nidini, M., Ntreta, M., Orsatti, M., Palazzolo, C., Palumbo, I., Parisi, A., Parma, P., Pavan, N., Pericolini, M., Pinto, F., Pistone, A., Pizzuti, V., Platania, A., Polli, C., Pomara, G., Ponti, E., Porcaro, A. B., Porpiglia, F., Pugliese, D., Pycha, A., Raguso, G., Rampini, A., Randone, D. F., Roboldi, V., Roscigno, M., Ruggieri, M. P., Ruoppo, G., Sanseverino, R., Santacaterina, A., Santarsieri, M., Santoni, R., Scagliarini, S., Scagliotti, G. V., Scanzi, M., Scarcia, M., Schiavina, R., Sciarra, A., Sciorio, C., Scolaro, T., Scuzzarella, S., Selvaggio, O., Serao, A., Serni, S., Signor, M. A., Silvani, M., Silvano, G., Silvestris, F., Simeone, C., Simone, V., Spagnoletti, G., Spinelli, M. G., Squillace, L., Tombolini, V., Toninelli, M., Triggiani, L., Trinchieri, A., Trodella, L. E., Trodella, L., Trombetta, C., Tronnolone, L., Tucci, M., Urzi, D., Valdagni, R., Valeriani, M., Vanoli, M., Vitali, E., Volpe, A., Zaramella, S., Zeccolini, G., Zini, G., Porreca, A, Noale, M, Artibani, W, Bassi, P, Bertoni, F, Bracarda, S, Conti, G, Corvò, R, Gacci, M, Graziotti, P, Magrini, S, Mirone, V, Montironi, R, Muto, G, Pecoraro, S, Ricardi, U, Russi, E, Tubaro, A, Zagonel, V, Crepaldi, G, Maggi, S, and Da Pozzo, L

Subjects
Male, 030232 urology & nephrology, Severity of Illness Index, Prostate cancer, 0302 clinical medicine, Quality of life, Activities of Daily Living, Diagnosis, Medicine, Age Factor, Prospective Studies, Prospective cohort study, Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA, Age Factors, Pros-IT CNR study, General Medicine, Health Survey, Middle Aged, Neoadjuvant Therapy, 3. Good health, Italy, 030220 oncology & carcinogenesis, lcsh:R858-859.7, Regression Analysis, Public Health, Human, Diagnosi, prostate cancer, survival, quality of life, medicine.medical_specialty, lcsh:Computer applications to medicine. Medical informatics, Regression Analysi, 03 medical and health sciences, Percutaneous Coronary Intervention, Internal medicine, Severity of illness, Humans, Aged, Cancer staging, business.industry, Research, Environmental and Occupational Health, Public Health, Environmental and Occupational Health, Prostatic Neoplasms, Cancer, medicine.disease, Health Surveys, Comorbidity, Quality of Life, Prospective Studie, Settore MED/24, Prostatic Neoplasm, business, Sexual function
Abstract

Background The National Research Council (CNR) prostate cancer monitoring project in Italy (Pros-IT CNR) is an observational, prospective, ongoing, multicentre study aiming to monitor a sample of Italian males diagnosed as new cases of prostate cancer. The present study aims to present data on the quality of life at time prostate cancer is diagnosed. Methods One thousand seven hundred five patients were enrolled. Quality of life is evaluated at the time cancer was diagnosed and at subsequent assessments via the Italian version of the University of California Los Angeles-Prostate Cancer Index (UCLA-PCI) and the Short Form Health Survey (SF-12). Results At diagnosis, lower scores on the physical component of the SF-12 were associated to older ages, obesity and the presence of 3+ moderate/severe comorbidities. Lower scores on the mental component were associated to younger ages, the presence of 3+ moderate/severe comorbidities and a T-score higher than one. Urinary and bowel functions according to UCLA-PCI were generally good. Almost 5% of the sample reported using at least one safety pad daily to control urinary loss; less than 3% reported moderate/severe problems attributable to bowel functions, and sexual function was a moderate/severe problem for 26.7%. Diabetes, 3+ moderate/severe comorbidities, T2 or T3-T4 categories and a Gleason score of eight or more were significantly associated with lower sexual function scores at diagnosis. Conclusions Data collected by the Pros-IT CNR study have clarified the baseline status of newly diagnosed prostate cancer patients. A comprehensive assessment of quality of life will allow to objectively evaluate outcomes of different profile of care.

Published
2018

196. A0041 - Primary retroperitoneal germ-cell tumors (pR-GCT): Evaluation of treatment outcomes of an international collaboration (PRIMERE study-IGG05).

Author

Nazzani, S., Giannatempo, P., Bernasconi, V., Silvani, C., Mego, M., Taglialatela, I., Bimbatti, D., Secondino, S., De Giorgi, U., Claps, M., Biasoni, D., Catanzaro, M., Zimatore, M., Torelli, T., Stagni, S., Macchi, A., Tesone, A., Pedrazzoli, P., Basso, U., and Procopio, G.

Subjects
*TREATMENT effectiveness, *GERM cell tumors, *TUMORS
Published
2024
Full Text
View/download PDF

197. Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study

Author

Michele Milella, Orazio Caffo, Giuseppe Procopio, Francesco Carrozza, Nicola Battelli, Sebastiano Buti, Marc R. Matrana, Francesco Massari, Javier Molina-Cerrillo, Lorena Incorvaia, Veronica Mollica, Giuseppe Fornarini, Umberto Basso, Matteo Santoni, Gaetano Aurilio, Fady Farag, Enrique Grande, Mimma Rizzo, Ugo De Giorgi, Roberto Iacovelli, Alessandro Rizzo, Santoni M., Massari F., Grande E., Procopio G., Matrana M.R., Rizzo M., De Giorgi U., Basso U., Milella M., Iacovelli R., Aurilio G., Incorvaia L., Buti S., Caffo O., Fornarini G., Carrozza F., Mollica V., Rizzo A., Farag F., Molina-Cerrillo J., and Battelli N.

Subjects
Male, Oncology, Cancer Research, medicine.medical_specialty, Multivariate analysis, Cabozantinib, Pyridines, chemistry.chemical_compound, Renal cell carcinoma, Internal medicine, medicine, Humans, Anilides, Pharmacology (medical), Carcinoma, Renal Cell, Sarcomatoid Differentiation, Retrospective Studies, business.industry, Hazard ratio, Cell Differentiation, medicine.disease, Kidney Neoplasms, Confidence interval, chemistry, Male patient, Female, business, Kidney cancer
Abstract

Background: Renal cell carcinoma with sarcomatoid differentiation is a highly aggressive form of kidney cancer. Objective: We aimed to analyze the outcomes of patients treated with cabozantinib for metastatic renal cell carcinoma with sarcomatoid features. Methods: We retrospectively collected data from 16 worldwide centers. Overall survival and progression-free survival were analyzed using Kaplan–Meier curves. Cox proportional models were used for univariate and multivariate analyses. Results: We collected data from 66 patients with metastatic sarcomatoid renal cell carcinoma receiving cabozantinib as second-line (51%) or third-line (49%) therapy. The median progression-free survival from the start of cabozantinib was 7.59 months (95% confidence interval [CI] 5.75−17.49) and was longer in male patients (8.81 vs 5.95 months, p = 0.042) and in patients without bone metastases (7.59 vs 5.11 months, p = 0.010); the median overall survival was 9.11 months (95% CI 7.13−23.80). At the multivariate analysis, female sex (hazard ratio = 1.81; 95% CI 1.02−3.37,p = 0.046), bone metastases (hazard ratio = 2.62; 95% CI 1.34−5.10, p = 0.005), and International Metastatic Renal Cell Carcinoma Database Consortium criteria (hazard ratio = 3.04; 95% CI 1.54−5.99, p = 0.001) were significant predictors of worse overall survival. Conclusions: Our data show that cabozantinib is active in pretreated patients with sarcomatoid renal cell carcinoma. Biomarkers are needed in this field to select patients for multi-kinase inhibitors or other options.

Published
2021
Full Text
View/download PDF

198. 1476P Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study.

Author

Rebuzzi, S.E., Rescigno, P., Signori, A., Brunelli, M., Galuppini, F., Vellone, V.G., Gaggero, G., Maruzzo, M., Milella, M., Vignani, F., Cavo, A., Basso, U., Catalano, F., Murianni, V., Cremante, M., Damassi, A., Llaja Obispo, M.A., Banna, G.L., Buti, S., and Fornarini, G.

Subjects
*RENAL cell carcinoma, *TUMOR microenvironment, *IMMUNOTHERAPY, *METASTASIS
Published
2022
Full Text
View/download PDF

199. Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib

Author

Sara Elena Rebuzzi, Luigi Cerbone, Alessio Signori, Matteo Santoni, Veronica Murianni, Ugo De Giorgi, Giuseppe Procopio, Camillo Porta, Michele Milella, Umberto Basso, Francesco Massari, Marco Maruzzo, Roberto Iacovelli, Nicola Battelli, Luca Carmisciano, Giuseppe Luigi Banna, Sebastiano Buti, Giuseppe Fornarini, Rebuzzi S.E., Cerbone L., Signori A., Santoni M., Murianni V., De Giorgi U., Procopio G., Porta C., Milella M., Basso U., Massari F., Maruzzo M., Iacovelli R., Battelli N., Carmisciano L., Banna G.L., Buti S., and Fornarini G.

Subjects
renal cell carcinoma, Oncology, cabozantinib, target therapy, clinical factors, biomarkers, prognostic score, biomarker, clinical factor
Abstract

Background: The addition of neutrophil-to-lymphocyte ratio (NLR) and bone metastases to the International Metastatic RCC Database Consortium (IMDC) score (by the Meet-URO score) has been shown to better stratify pretreated metastatic renal cell carcinoma (mRCC) patients receiving nivolumab. This study aimed to validate the Meet-URO score in patients receiving cabozantinib to assess its predictivity and prognostic role. Methods: A multicenter retrospective analysis evaluated mRCC patients receiving ⩾second-line cabozantinib. NLR, IMDC score and bone metastases were assessed before the start of cabozantinib. The primary endpoint was overall survival (OS). Harrell’s c-index was calculated to compare the accuracy of the prediction of the two scores. Results: Overall, 174 mRCC patients received cabozantinib as second and third line (51.7% and 48.3%, respectively) with a median follow-up of 6.8 months. A shorter median overall survival (mOS) was observed for the IMDC poor-risk group, NLR ⩾3.2 and the presence of bone metastases, while the IMDC intermediate-risk group had a similar mOS to the favourable-risk one. Applying the Meet-URO score, three risk groups were identified: group 1 (55.2% of patients) with a score of 0–3, group 2 (38.5%) with a score of 4–8 and group 3 (6.3%) with a score of 9. Compared to group 1 (mOS: 39.4 months), a statistically significant worse mOS was observed in group 2 (11.2 months) and group 3 (3.2 months) patients, respectively. The Meet-URO c-index score was 0.640, showing a higher discriminative ability than the IMDC score ( c-index: 0.568). Conclusion: This analysis showed that the Meet-URO score provides a more accurate prognostic stratification than the IMDC score in mRCC patients treated with ⩾second-line cabozantinib besides nivolumab. Moreover, it is an easy-to-use tool with no additional costs for clinical practice (web-calculator is available at: https://proviso.shinyapps.io/Meet-URO15_score/ ). Future investigations will include the application of the Meet-URO score to the first-line immunotherapy-based combination therapies.

Published
2022

200. Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study

Author

Matteo Brunelli, Guido Martignoni, Giorgio Malpeli, Alessandro Volpe, Luca Cima, Maria Rosaria Raspollini, Mattia Barbareschi, Alessandro Tafuri, Giulia Masi, Luisa Barzon, Serena Ammendola, Manuela Villanova, Maria Angela Cerruto, Michele Milella, Sebastiano Buti, Melissa Bersanelli, Giuseppe Fornarini, Sara Elena Rebuzzi, Valerio Gaetano Vellone, Gabriele Gaggero, Giuseppe Procopio, Elena Verzoni, Sergio Bracarda, Martina Fanelli, Roberto Sabbatini, Rodolfo Passalacqua, Bruno Perrucci, Maria Olga Giganti, Maddalena Donini, Stefano Panni, Marcello Tucci, Veronica Prati, Cinzia Ortega, Anna Caliò, Albino Eccher, Filippo Alongi, Giovanni Pappagallo, Roberto Iacovelli, Alessandra Mosca, Paolo Umari, Ilaria Montagnani, Stefano Gobbo, Francesco Atzori, Enrico Munari, Marco Maruzzo, Umberto Basso, Francesco Pierconti, Carlo Patriarca, Piergiuseppe Colombo, Alberto Lapini, Giario Conti, Roberto Salvioni, Enrico Bollito, Andrea Cossarizza, Francesco Massari, Mimma Rizzo, Renato Franco, Federica Zito-Marino, Yoseba Aberasturi Plata, Francesca Galuppini, Marta Sbaraglia, Matteo Fassan, Angelo Paolo Dei Tos, Maurizio Colecchia, Holger Moch, Maurizio Scaltriti, Camillo Porta, Brett Delahunt, Gianluca Giannarini, Roberto Bortolus, Pasquale Rescigno, Giuseppe Luigi Banna, Alessio Signori, Miguel Angel Llaja Obispo, Roberto Perris, Alessandro Antonelli, Brunelli, Matteo, Martignoni, Guido, Malpeli, Giorgio, Volpe, Alessandro, Cima, Luca, Raspollini, Maria Rosaria, Barbareschi, Mattia, Tafuri, Alessandro, Masi, Giulia, Barzon, Luisa, Ammendola, Serena, Villanova, Manuela, Cerruto, Maria Angela, Milella, Michele, Buti, Sebastiano, Bersanelli, Melissa, Fornarini, Giuseppe, Rebuzzi, Sara Elena, Vellone, Valerio Gaetano, Gaggero, Gabriele, Procopio, Giuseppe, Verzoni, Elena, Bracarda, Sergio, Fanelli, Martina, Sabbatini, Roberto, Passalacqua, Rodolfo, Perrucci, Bruno, Giganti, Maria Olga, Donini, Maddalena, Panni, Stefano, Tucci, Marcello, Prati, Veronica, Ortega, Cinzia, Caliò, Anna, Eccher, Albino, Alongi, Filippo, Pappagallo, Giovanni, Iacovelli, Roberto, Mosca, Alessandra, Umari, Paolo, Montagnani, Ilaria, Gobbo, Stefano, Atzori, Francesco, Munari, Enrico, Maruzzo, Marco, Basso, Umberto, Pierconti, Francesco, Patriarca, Carlo, Colombo, Piergiuseppe, Lapini, Alberto, Conti, Giario, Salvioni, Roberto, Bollito, Enrico, Cossarizza, Andrea, Massari, Francesco, Rizzo, Mimma, Franco, Renato, Zito-Marino, Federica, Aberasturi Plata, Yoseba, Galuppini, Francesca, Sbaraglia, Marta, Fassan, Matteo, Dei Tos, Angelo Paolo, Colecchia, Maurizio, Moch, Holger, Scaltriti, Maurizio, Porta, Camillo, Delahunt, Brett, Giannarini, Gianluca, Bortolus, Roberto, Rescigno, Pasquale, Banna, Giuseppe Luigi, Signori, Alessio, Obispo, Miguel Angel Llaja, Perris, Roberto, Antonelli, Alessandro, Brunelli M., Martignoni G., Malpeli G., Volpe A., Cima L., Raspollini M.R., Barbareschi M., Tafuri A., Masi G., Barzon L., Ammendola S., Villanova M., Cerruto M.A., Milella M., Buti S., Bersanelli M., Fornarini G., Rebuzzi S.E., Vellone V.G., Gaggero G., Procopio G., Verzoni E., Bracarda S., Fanelli M., Sabbatini R., Passalacqua R., Perrucci B., Giganti M.O., Donini M., Panni S., Tucci M., Prati V., Ortega C., Calio A., Eccher A., Alongi F., Pappagallo G., Iacovelli R., Mosca A., Umari P., Montagnani I., Gobbo S., Atzori F., Munari E., Maruzzo M., Basso U., Pierconti F., Patriarca C., Colombo P., Lapini A., Conti G., Salvioni R., Bollito E., Cossarizza A., Massari F., Rizzo M., Franco R., Zito-Marino F., Plata Y.A., Galuppini F., Sbaraglia M., Fassan M., Dei Tos A.P., Colecchia M., Moch H., Scaltriti M., Porta C., Delahunt B., Giannarini G., Bortolus R., Rescigno P., Banna G.L., Signori A., Obispo M.A.L., Perris R., and Antonelli A.

Subjects
angiogenesis, clear cell renal cell carcinoma, tumor sampling, intratumoral heterogeneity, immunity, immunohistochemistry, Medicine (miscellaneous), angiogenesi
Abstract

We aimed to overcome intratumoral heterogeneity in clear cell renal cell carcinoma (clearRCC). One hundred cases of clearRCC were sampled. First, usual standard sampling was applied (1 block/cm of tumor); second, the whole tumor was sampled, and 0.6 mm cores were taken from each block to construct a tissue microarray; third, the residual tissue, mapped by taking pieces 0.5 × 0.5 cm, reconstructed the entire tumor mass. Precisely, six randomly derived pieces of tissues were placed in each cassette, with the number of cassettes being based on the diameter of the tumor (called multisite 3D fusion). Angiogenic and immune markers were tested. Routine 5231 tissue blocks were obtained. Multisite 3D fusion sections showed pattern A, homogeneous high vascular density (10%), pattern B, homogeneous low vascular density (8%) and pattern C, heterogeneous angiogenic signatures (82%). PD-L1 expression was seen as diffuse (7%), low (33%) and absent (60%). Tumor-infiltrating CD8 scored high in 25% (pattern hot), low in 65% (pattern weak) and zero in 10% of cases (pattern desert). Grading was upgraded in 26% of cases (G3–G4), necrosis and sarcomatoid/rhabdoid characters were observed in, respectively, 11 and 7% of cases after 3D fusion (p = 0.03). CD8 and PD-L1 immune expressions were higher in the undifferentiated G4/rhabdoid/sarcomatoid clearRCC subtypes (p = 0.03). Again, 22% of cases were set to intermediate to high risk of clinical recurrence due to new morphological findings of all aggressive G4, sarcomatoid/rhabdoid features by using 3D fusion compared to standard methods (p = 0.04). In conclusion, we propose an easy-to-apply multisite 3D fusion sampling that negates bias due to tumor heterogeneity.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results